Abstract
Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have